Sonali M Smith

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi request reprint Something old, something new
    Sonali Smith
    Lymphoma Program, Univesity of Chicago, IL 60637, USA
    Leuk Lymphoma 47:576-7. 2006
  2. doi request reprint The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)
    Sonali M Smith
    Section of Hematology Oncology, Lymphoma Program, University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 54:1405-10. 2013
  3. doi request reprint Targeting mTOR in mantle cell lymphoma: current and future directions
    Sonali M Smith
    Section of Hematology Oncology, The University of Chicago, 5841 S Maryland Avenue, MC2115, Chicago, IL 60637, USA
    Best Pract Res Clin Haematol 25:175-83. 2012
  4. pmc Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium
    Sonali M Smith
    The University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 28:4740-6. 2010
  5. doi request reprint Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691
    S M Smith
    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 50:1606-17. 2009
  6. pmc Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant
    Sonali M Smith
    Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
    Biol Blood Marrow Transplant 14:904-12. 2008
  7. doi request reprint Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B
    Sonali M Smith
    The University of Chicago, Chicago, IL 60637, USA
    Br J Haematol 140:313-9. 2008
  8. ncbi request reprint Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906
    Sonali M Smith
    University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 47:1511-7. 2006
  9. ncbi request reprint Reduced-intensity transplantation for lymphoma
    Sonali M Smith
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, 5841 South Maryland Avenue, MC2115, IL 60637, USA
    Curr Treat Options Oncol 7:295-305. 2006
  10. ncbi request reprint Nonmyeloablative transplantation for lymphoma
    Sonali M Smith
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 South Maryland Avenue MC2115, Chicago, IL 60637, USA
    Curr Treat Options Oncol 4:261-8. 2003

Detail Information

Publications36

  1. ncbi request reprint Something old, something new
    Sonali Smith
    Lymphoma Program, Univesity of Chicago, IL 60637, USA
    Leuk Lymphoma 47:576-7. 2006
  2. doi request reprint The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)
    Sonali M Smith
    Section of Hematology Oncology, Lymphoma Program, University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 54:1405-10. 2013
    ..6 months. Galiximab was well-tolerated, with minimal grade 3 or 4 toxicities. Despite this preclinical rationale, single-agent galiximab had limited activity in heavily pretreated Hodgkin lymphoma...
  3. doi request reprint Targeting mTOR in mantle cell lymphoma: current and future directions
    Sonali M Smith
    Section of Hematology Oncology, The University of Chicago, 5841 S Maryland Avenue, MC2115, Chicago, IL 60637, USA
    Best Pract Res Clin Haematol 25:175-83. 2012
    ..Several dozen ongoing clinical trials should help refine the optimal use of mTOR inhibitors for MCL patients...
  4. pmc Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium
    Sonali M Smith
    The University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 28:4740-6. 2010
    ..The mammalian target of rapamycin (mTOR) pathway is a validated target in mantle cell lymphoma, but has not been extensively evaluated in other lymphomas...
  5. doi request reprint Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691
    S M Smith
    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 50:1606-17. 2009
    ....
  6. pmc Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant
    Sonali M Smith
    Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
    Biol Blood Marrow Transplant 14:904-12. 2008
    ..HCT2 should be considered for patients with relapsed HL or NHL after HCT1 without alternative allogeneic stem cell transplant options...
  7. doi request reprint Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B
    Sonali M Smith
    The University of Chicago, Chicago, IL 60637, USA
    Br J Haematol 140:313-9. 2008
    ..Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide...
  8. ncbi request reprint Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906
    Sonali M Smith
    University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 47:1511-7. 2006
    ..The activity in Burkitt's lymphoma should be investigated further...
  9. ncbi request reprint Reduced-intensity transplantation for lymphoma
    Sonali M Smith
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, 5841 South Maryland Avenue, MC2115, IL 60637, USA
    Curr Treat Options Oncol 7:295-305. 2006
    ....
  10. ncbi request reprint Nonmyeloablative transplantation for lymphoma
    Sonali M Smith
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 South Maryland Avenue MC2115, Chicago, IL 60637, USA
    Curr Treat Options Oncol 4:261-8. 2003
    ..Nonmyeloablative hematopoietic stem cell transplantation may broaden the applicability of allogeneic transplantation in malignant lymphomas, especially for indolent subtypes...
  11. ncbi request reprint CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review
    Sheetal M Kircher
    Department of Internal Medicine, University of Chicago Hospitals, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    J Gastrointest Cancer 38:59-62. 2007
    ..Substantial portions of patients either have no prior diagnosis of celiac disease or have a subacute course of celiac disease followed by EATL diagnosis...
  12. doi request reprint Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas
    Xavier Poiré
    Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA
    Leuk Lymphoma 51:1241-50. 2010
    ..Post-ASCT immunomodulation with rituximab, IL-2, and GM-CSF was feasible and safe, but not all patients were able to continue on to post-ASCT immunotherapy...
  13. ncbi request reprint Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant
    Zeba N Singh
    Section of Hematopathology, Department of Pathology, University of Chicago, Chicago, IL 60637, USA
    Am J Clin Pathol 127:197-205. 2007
    ..We found only a borderline difference in median survival of patients with an initial t-MDS diagnosis compared with patients with an initial t-AML diagnosis...
  14. pmc T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse
    Vaishalee P Kenkre
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA
    Leuk Lymphoma 52:214-22. 2011
    ..Our outcomes challenge the utility of the common practice of prophylactic DLI after T-depleted transplant for lymphoma...
  15. pmc Pre-diagnosis cigarette smoking and overall survival in non-Hodgkin lymphoma
    Nicholas J Ollberding
    Division of Biostatistics and Epidemiology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA Department of Health Studies, University of Chicago, Chicago, IL, USA
    Br J Haematol 163:352-6. 2013
    ..The inferior survival was more pronounced for follicular than for diffuse large B cell lymphoma. Pre-diagnosis cigarette smoking may adversely impact the survival of NHL patients. ..
  16. doi request reprint A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas
    Jane E Churpek
    Department of Medicine, Section of Hematology Oncology, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Cancer 119:1683-9. 2013
    ..Ixabepilone (BMS-247550, epothilone B analog), a potent inhibitor of tubulin disassembly, has promising preclinical and early-phase clinical activity in drug-resistant malignancies...
  17. doi request reprint Dietary nitrate and nitrite intake and risk of non-Hodgkin lymphoma
    Briseis Aschebrook-Kilfoy
    Department of Health Studies, University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 54:945-50. 2013
    ..Although there were some increases in risk that support the N-nitroso hypothesis, they were not significant and do not confer strong evidence of an association...
  18. ncbi request reprint CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review
    Sheetal M Kircher
    Department of Internal Medicine, University of Chicago Hospitals, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    J Gastrointest Cancer 38:19-23. 2007
    ..We also discuss our experience with the use of fluoro-2-deoxy-D-glucose positron emission tomography in monitoring treatment response...
  19. ncbi request reprint The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras
    Chadi Nabhan
    Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois
    Am J Hematol 89:633-8. 2014
    ..Am. J. Hematol. 89:633-638, 2014. © 2014 Wiley Periodicals, Inc. ..
  20. doi request reprint An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA
    Briseis Aschebrook-Kilfoy
    Department of Health Studies, University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 54:1677-83. 2013
    ..In addition, we found that the gender and white-to-black disparities have grown over time. Our findings may impact MCL etiologic investigation and treatment research...
  21. pmc Phytanic acid and the risk of non-Hodgkin lymphoma
    Nicholas J Ollberding
    Department of Health Studies, University of Chicago, Chicago, IL, USA
    Carcinogenesis 34:170-5. 2013
    ..Our results provide support that total phytanic acid and phytanic acid-containing foods may increase NHL risk...
  22. doi request reprint Personalized treatment of lymphoma: promise and reality
    Erika Ramsdale
    Lymphoma Program, The University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 38:225-35. 2011
    ..An important unmet need is the implementation of these tools into treatment choices for individual patients, and this is the focus of intense ongoing research...
  23. ncbi request reprint Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
    Sonali M Smith
    Section of Hematology Oncology, Department of Medicine, MC2115, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Blood 102:43-52. 2003
    ..0001). Median survival time after diagnosis of t-MDS/t-AML was 8 months; survival at 5 years was less than 10%. These data confirm and extend previous associations between clinical, morphologic, and cytogenetic findings in t-MDS/t-AML...
  24. pmc Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era
    Andrew M Evens
    DO, MSc, Division of Hematology Oncology, 676 N St Clair S, Suite 850, Chicago, IL, 60611, USA
    J Clin Oncol 28:1038-46. 2010
    ..In addition, clinical factors at diagnosis identified patients with markedly divergent outcomes...
  25. ncbi request reprint Management of relapsed diffuse large B-cell lymphoma
    Vaishalee Padgaonkar Kenkre
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637, USA
    Curr Oncol Rep 10:393-403. 2008
    ..This review outlines the current approach to the management of relapsed diffuse large B-cell lymphoma, with an emphasis on newer peritransplant therapies...
  26. ncbi request reprint Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant
    Koen Van Besien
    University of Chicago, Section of Hematology Oncology, Rm I 209, 5841 South Maryland Ave, Chicago, Illinois 60637, USA
    Curr Treat Options Oncol 6:279-87. 2005
    ..New strategies designed to prevent relapse after autograft include cytokine therapy such as interleukin-2 in combination with monoclonal antibodies and the use of autologous antilymphoma vaccines...
  27. ncbi request reprint Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation
    Andrew S Artz
    Section of Hematology Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Biol Blood Marrow Transplant 12:954-64. 2006
    ..001) and enhanced prognostic power over the CCI alone (P = .018). Prospective studies evaluating more comprehensive functional and comorbidity measurements are warranted...
  28. pmc Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma
    Sonali M Smith
    University of Chicago Hospitals, Chicago, USA
    J Clin Oncol 31:3100-9. 2013
    ..To analyze outcomes of hematopoietic cell transplantation (HCT) in T-cell non-Hodgkin lymphoma...
  29. ncbi request reprint Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities
    Miroslav Djokic
    Department of Pathology, University of Chicago Medical Center, 5841 S Maryland, MC 0008, Illinois 60637, USA
    Genes Chromosomes Cancer 45:313-8. 2006
    ..PTLD with trisomy 9 and/or 11 developed early after transplant, presenting as Epstein-Barr virus-positive large B-cell lymphoma with prolonged survival...
  30. doi request reprint The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma
    Sonali M Smith
    Section of Hematology Oncology, Department of Medicine and The University of Chicago Comprehensive Cancer Center, The University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    Blood Cells Mol Dis 45:317-23. 2010
    ..Here we summarize current knowledge regarding MYC in lymphomas other than Burkitt lymphoma, with an emphasis on transcriptional, epigenetic, clinical, and microenvironmental consequences...
  31. ncbi request reprint Clinical development of mTOR inhibitors: a focus on lymphoma
    Sonali M Smith
    The University of Chicago Hospitals, Chicago, IL 60637, USA
    Rev Recent Clin Trials 2:103-10. 2007
    ..Here we review the rationale for testing mTOR inhibitors in lymphoma, the phase 1 trials influencing dose and schedule of mTOR inhibitors, and summarize the clinical results in obtained to date in patients with lymphoma...
  32. doi request reprint Meat intake and risk of non-Hodgkin lymphoma
    Briseis Aschebrook-Kilfoy
    Department of Health Studies, University of Chicago, 5841 South Maryland Avenue, N101B, Chicago, IL 60637, USA
    Cancer Causes Control 23:1681-92. 2012
    ....
  33. doi request reprint Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies
    Chadi Nabhan
    Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL, USA
    Leuk Lymphoma 53:770-8. 2012
    ....
  34. doi request reprint Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphoma
    Brian C H Chiu
    Department of Health Studies, University of Chicago, 5841 South Maryland Avenue, MC 2007, Chicago, IL 60637, USA
    Cancer Causes Control 22:1183-95. 2011
    ..Few studies have evaluated the potential association between consumption of fruit and vegetables and non-Hodgkin lymphoma (NHL) by histologic subtype, and the results of these studies have been inconsistent...
  35. ncbi request reprint Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells
    Sonali M Smith
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 52:291-302. 2003
    ..Ifosfamide is a nitrogen mustard with growing clinical applications; effective modulation may lead to improved efficacy. We thus undertook a preliminary investigation of BG's effects on ifosfamide and ifosfamide derivatives in vitro...
  36. ncbi request reprint Successful allogeneic transplantation of patients with suspected prior invasive mold infection
    Brian T Hill
    Department of Internal Medicine, Cancer Research Center, University of Chicago, IL, USA
    Leuk Lymphoma 48:1799-805. 2007
    ..We conclude that suspected prior invasive fungal infection should not preclude the use of allogeneic stem cell transplantation...